Following completion of her residency in Radiation Oncology, Dr Crittenden would like to pursue a career in academic medicine continuing to do research into novel cancer therapies and caring for patients.

Resident year: PGY 2 (1st year in Radiation Medicine)

Dept: Radiation Medicine

Undergraduate: Bachelor of Arts at the University of Oregon in Eugene, Oregon with a dual degree in Mathematics and Chemistry in 1997.

Graduate and Medical School: MD/PhD from Mayo Clinic, College of Medicine in Rochester, Minnesota in 2004. Her PhD is in Immunology. Her specific area of research was in development of gene therapy approaches using immunomodulatory agents for the treatment of cancer.

Internship: Preliminary medicine internship at Providence Portland in 2005.

Publications:

Gough MJ, Crittenden MR, Thanarajasingham U, Sanchez-Perez L, Thompson J, Jevremovic D, Vile RG. (2005) Gene therapy to manipulate effector T cell trafficking to tumors for immunotherapy. J Immunol 174: 5766-73

Crittenden MR, Thanarajasingham U, Vile RG, Gough MJ. (2005) Intratumoral Immunotherapy: strategies that use the tumor site to enhance anti-tumor immunity [Review]. Immunology 114: 11-22

Bonnotte B, Crittenden M, Larmonier N, Gough M, Vile RG (2004) MIP-3 alpha Transfection into a Rodent Tumor Cell Line Increases Intratumoral Dendritic Cell Infiltration but Enhances (Facilitates) Tumor Growth and Decreases Immunogenicity. J Immunol 173: 4929-4935

Gough MJ, Melcher AA, Crittenden MR, Sanchez L, Voellmy R, Vile RG (2004) Induction of cell stress through gene transfer of an engineered heat shock transcription factor enhances tumor immunogenicity. Gene Therapy 11(13): 1099-1104  

Crittenden MR, Gough MJ, Harrington K, Olivier K, Thompson J, & Vile RG (2003) Expression of Inflammatory Chemokines Combined with Local Tumor Destruction Enhances Tumor Regression and Long Term Immunity. Cancer Research. 63: 5505-12

Crittenden MR, Gough MJ, Chester J, Kottke T, Thompson J, Ruchatz A, Clackson T, Luic Cosset F, Chong H, Diaz R-M, Harrington K, Alvarez Vallina L & Vile RG. (2003) Pharmacologically regulated production of targeted retrovirus from T cells for systemic anti-tumor gene therapy. Cancer Research. 63: 3173-80 

Harrington K, Alvarez-Vallina L, Crittenden M, Gough M, Chong H, Diaz RM, Vassaux G, Lemoine N, Vile R (2002) Cells as vehicles for cancer gene therapy: the missing link between targeted vectors and systemic delivery? Human Gene Therapy. 13(11): 1263-80

Chester J, Ruchatz A, Gough M, Crittenden M, Chong H, Loic-Cosset F, Diaz RM, Harrington K, Alvarez-Vallina L, Vile R. (2002) Tumor antigen-specific induction of transcriptionally targeted retroviral vectors from chimeric immune receptor-modified T cells. Nature Biotechnology 20: 256-63

Gough MJ, Melcher AA, Ahmed A, Crittenden MR, Riddle DS, Linardakis E, Ruchatz AN, Emiliusen LM & Vile RG. (2001) Macrophages orchestrate the immune response to tumor cell death. Cancer Research 61(19): 7240-7